• If you are wondering whether Viridian Therapeutics at around US$26.98 is offering good value or asking too much, you are in the right place.
• The stock has recently seen mixed returns, with a 7 day move of 5.9% decline and a 30 day return of 4.0% decline, while still sitting on a 76.8% gain over the past year and 12.1% decline year to date.
• Recent news coverage has focused on Viridian Therapeutics as a biotech name that continues to attract attention from investors watching the sector. This adds context to the share price strength over the past 12 months. At the same time, ongoing commentary on risk in smaller biotech stocks keeps short term moves in focus for traders weighing potential upside against volatility.
• Viridian Therapeutics currently has a valuation score of 3 out of 6, which reflects where it screens as undervalued on several checks. Next you will see how approaches like DCF and multiples compare, before finishing with a broader way to think about what valuation really means for this stock.

Approach 1: Viridian Therapeutics Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model projects a company’s future cash flows and then discounts them back to today’s value, aiming to estimate what the business might be worth right now.

For Viridian Therapeutics, the model used is a 2 Stage Free Cash Flow to Equity approach based on cash flow projections. The latest twelve month free cash flow is a loss of $278.3 million, so the story here is focused on future potential cash generation rather than current profitability.

Analyst inputs and extrapolations feed into ten year projections, moving from expected losses in the next few years to projected free cash flow of $533.995 million by 2030. Simply Wall St then extends those estimates out to 2035 using its own assumptions and discounts each year’s cash flow back to today using its chosen rate.

On this basis, the model arrives at an estimated intrinsic value of about $168.28 per share. This implies the stock is around 84.0% undervalued compared with the current price of roughly $26.98.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Viridian Therapeutics is undervalued by 84.0%. Track this in your watchlist or portfolio, or discover 52 more high quality undervalued stocks.

Approach 2: Viridian Therapeutics Price vs Sales

P/S is often used for companies where profits are limited or volatile, because sales are usually more stable than earnings and still give you a sense of what investors are paying for each dollar of revenue.

In general, higher expected growth and lower perceived risk can justify a higher “normal” P/S multiple. Slower growth and higher risk tend to align with a lower multiple that investors are comfortable paying.

Viridian Therapeutics currently trades on a P/S ratio of 38.92x. This is well above the Biotechs industry average P/S of 10.70x and also above the peer average of 11.54x, which suggests the market is attaching a relatively rich sales multiple to the stock compared with many peers.

Simply Wall St’s Fair Ratio is a proprietary estimate of what Viridian Therapeutics’ P/S might be, based on factors such as earnings growth, profit margins, industry, market cap and risk profile. This makes it more tailored than a simple comparison with industry or peer averages, which treat all companies in the group as broadly similar.

The Fair Ratio for Viridian Therapeutics is 0.06x, which is far below the current 38.92x P/S. On this basis, the shares screen as expensive on a sales multiple view.

Result: OVERVALUED

P/S ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your Viridian Therapeutics Narrative

Earlier it was mentioned that there is an even better way to understand valuation, so Narratives are a tool that lets you write a clear story about Viridian Therapeutics, link that story to your own revenue, earnings and margin forecasts, and then see the fair value that flows from those assumptions.

A Narrative on Simply Wall St’s Community page connects three pieces: what you think is happening with the business, the financial forecast that matches that view, and the fair value that drops out of those numbers. All of this is shown next to the current share price so you can decide whether Viridian Therapeutics looks attractive or stretched for your approach.

Because Narratives sit on the platform used by millions of investors and update automatically when new earnings, filings or news are added, you can keep your view current without rebuilding spreadsheets as information changes.

For example, one Viridian Therapeutics Narrative on the Community page might set a much higher fair value based on optimistic assumptions, while another assigns a much lower fair value using cautious revenue and margin estimates. This shows how different viewpoints can lead to very different conclusions about the same stock.

Do you think there's more to the story for Viridian Therapeutics? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.